Minicircle’s XPRIZE Healthspan finalist status — a brief look at a gene‑therapy developer advancing to late-stage competition with plans for human trials.
Key Takeaways
- Minicircle advanced to the final 10 in the XPRIZE Healthspan competition for measurable rejuvenation trials
- Company received a $1 million finalist cash prize to support a placebo-controlled human clinical trial
- Minicircle’s trial will study a scalable combination gene therapy targeting adults aged fifty to eighty